Comparison
22q11 2 Deletion Syndrome Cn294181 vs 17 20 Lyase Deficiency Isolated C3277849
Clinical comparison between 22q11 2 Deletion Syndrome CN294181 and 17 20 Lyase Deficiency Isolated for differential diagnosis and treatment planning.
22q11 2 Deletion Syndrome Cn294181
A genetic condition where a small piece of chromosome 22 is missing. It can affect the heart, immune system, and development. Treatment involves managing symptoms across multiple specialties.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
6 comparison axes
Onset
22q11 2 Deletion Syndrome Cn294181
0-null
17 20 Lyase Deficiency Isolated C3277849
0-18
Onset patterns differ
Severity
22q11 2 Deletion Syndrome Cn294181
severe
17 20 Lyase Deficiency Isolated C3277849
severe
Different severity levels
Chronic
22q11 2 Deletion Syndrome Cn294181
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
Differing course
Communicable
22q11 2 Deletion Syndrome Cn294181
No
17 20 Lyase Deficiency Isolated C3277849
No
Different transmission
Body System
22q11 2 Deletion Syndrome Cn294181
congenital
17 20 Lyase Deficiency Isolated C3277849
endocrine
Same/different system
Category
22q11 2 Deletion Syndrome Cn294181
genetic
17 20 Lyase Deficiency Isolated C3277849
endocrine
Different category
Bottom line
22q11-2-deletion-syndrome-CN294181 and 17-20-lyase-deficiency-isolated-C3277849 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 22q11 2 Deletion Syndrome Cn294181 | 17 20 Lyase Deficiency Isolated C3277849 | Discriminating power |
|---|---|---|---|
| Congenital anomalies | Cardiac, palatal, immune, or developmental features may occur. | Primary features concern sex-hormone production rather than multiple congenital systems. | High |
| Sexual development | Not the defining feature, although reproductive issues can occur. | Impaired development of sexual characteristics is central in both sexes. | High |
| Onset pattern | Often recognized from birth or early childhood when anomalies are present. | May become evident from infancy through adolescence, especially around puberty. | Moderate |
When to favor each condition
Choose 22q11 2 Deletion Syndrome Cn294181 when
Multisystem congenital findings
Heart, palate, immune, or developmental involvement supports chromosomal evaluation.
High
Characteristic facial or palatal features
These are more consistent with 22q11.2 deletion than isolated lyase deficiency.
Moderate
Recurrent infections with congenital anomalies
Possible immune involvement warrants specialist assessment; it does not prove the diagnosis.
Moderate
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Disordered sexual development
A primary sex-steroid synthesis defect should be considered.
High
Pubertal delay or atypical puberty
Endocrine evaluation is appropriate; exact thresholds are not established here.
Moderate
Isolated endocrine presentation
Absence of broad congenital anomalies makes chromosomal deletion less likely but does not exclude it.
Low
How key tests differ
| Test | 22q11 2 Deletion Syndrome Cn294181 | 17 20 Lyase Deficiency Isolated C3277849 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or targeted deletion testing | May identify a 22q11.2 deletion. | Not expected to establish isolated lyase deficiency. | A positive genetic result supports the left diagnosis; clinical correlation remains necessary. |
| Steroid hormone profile | No specific pattern is established by the supplied data. | May show impaired sex-steroid production; cutoffs are not provided. | Abnormal results suggest an endocrine disorder but are not themselves a diagnosis. |
| CYP17A1 or related genetic testing | Not the primary test for 22q11.2 deletion. | May support isolated 17,20-lyase deficiency when clinically indicated. | Selection and interpretation require an endocrinology or genetics clinician. |
Prognosis comparison
22q11 2 Deletion Syndrome Cn294181
- Outcome
- Chronic and potentially severe, with outcome depending on affected organs and available care.
- Factors
- Cardiac, immune, developmental, and other organ involvement.
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic endocrine condition; outcome data are not established here.
- Factors
- Degree of sex-hormone deficiency, timing of recognition, and response to supervised treatment.
Time frame: Lifelong for both; individual course varies.
No comparative mortality or prevalence should be inferred from these descriptions.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac disease | Congenital heart disease may occur and needs surveillance. Not a defining complication in the supplied description. Any suspected cardiac finding requires clinical assessment. |
| Immune dysfunction | Immune problems and infections may occur. Not described as a core feature. Infection history alone cannot distinguish the conditions. |
| Hormone-related effects | Possible but not the principal described manifestation. Sex-hormone deficiency and its developmental effects are central. Hormone treatment decisions and doses are outside this comparison. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other is a rare enzyme disorder affecting sex hormones.
- HighSpecialist care
Management may involve genetics, cardiology, immunology, endocrinology, or developmental services as indicated.
- MediumTest meaning
An abnormal laboratory result is not automatically a diagnosis and should be interpreted by a clinician.